Kuros Biosciences reports results for the full year 2021

Financial highlights

  • CHF 30.7 million cash & cash equivalents, trade and other receivables at December 31, 2021
  • Product sales increased more than 100% to CHF 8.3 million
  • Received USD 6 million (CHF 5.5 million) milestone payments from Checkmate Pharmaceuticals
  • Received USD 7 million (CHF 6.4 million) up front with USD 166.5 million in potential future revenues under royalty purchase agreement with XOMA
  • Total revenues of CHF 13.8 million (versus CHF 4.0 million in 2020), supported by Checkmate agreement

Operational highlights

  • Commercial rollout MagnetOs in U.S. and Europe on track
  • Enrolled more than 50% of patients in first stage of in Phase II spine clinical study of Fibrin-PTH
  • Over 90% of patients enrolled in MaXa clinical study with MagnetOs

back